JP2016505546A5 - - Google Patents

Download PDF

Info

Publication number: JP2016505546A5
Authority: JP; Japan
Prior art keywords: kabat; cdr; vegf; seq; variant
Prior art date: 2013-11-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

JP2015545453A

Other languages

English (en)

Japanese (ja)

Other versions

JP2016505546A (ja

Filing date

2013-11-27

Publication date

2017-01-12

2013-11-27 Application filed filed Critical

2013-11-27 Priority claimed from PCT/US2013/072335 external-priority patent/WO2014085654A1/en

2016-02-25 Publication of JP2016505546A publication Critical patent/JP2016505546A/ja

2017-01-12 Publication of JP2016505546A5 publication Critical patent/JP2016505546A5/ja

Status Ceased legal-status Critical Current

Links

NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 32
230000035772 mutation Effects 0.000 claims 6
239000008194 pharmaceutical composition Substances 0.000 claims 6
206010028980 Neoplasm Diseases 0.000 claims 4
201000011510 cancer Diseases 0.000 claims 4
206010061289 metastatic neoplasm Diseases 0.000 claims 4
241000282412 Homo Species 0.000 claims 3
206010064930 age-related macular degeneration Diseases 0.000 claims 3
208000002780 macular degeneration Diseases 0.000 claims 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 2
125000003275 alpha amino acid group Chemical group 0.000 claims 2
239000012634 fragment Substances 0.000 claims 2
208000026278 immune system disease Diseases 0.000 claims 2
230000001394 metastastic effect Effects 0.000 claims 2
208000011645 metastatic carcinoma Diseases 0.000 claims 2
208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
208000023328 Basedow disease Diseases 0.000 claims 1
206010006187 Breast cancer Diseases 0.000 claims 1
208000026310 Breast neoplasm Diseases 0.000 claims 1
102100033553 Delta-like protein 4 Human genes 0.000 claims 1
206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
208000015023 Graves' disease Diseases 0.000 claims 1
101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 1
108060003951 Immunoglobulin Proteins 0.000 claims 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
206010030113 Oedema Diseases 0.000 claims 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
239000000427 antigen Substances 0.000 claims 1
102000036639 antigens Human genes 0.000 claims 1
108091007433 antigens Proteins 0.000 claims 1
210000001072 colon Anatomy 0.000 claims 1
201000011190 diabetic macular edema Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000000694 effects Effects 0.000 claims 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
102000018358 immunoglobulin Human genes 0.000 claims 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
230000000306 recurrent effect Effects 0.000 claims 1
230000002207 retinal effect Effects 0.000 claims 1
208000004644 retinal vein occlusion Diseases 0.000 claims 1
206010039073 rheumatoid arthritis Diseases 0.000 claims 1
238000006467 substitution reaction Methods 0.000 claims 1

JP2015545453A 2012-11-30 2013-11-27 抗ｖｅｇｆ抗体及びこれらの使用 Ceased JP2016505546A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261732256P	2012-11-30	2012-11-30
US61/732,256		2012-11-30
PCT/US2013/072335 WO2014085654A1 (en)	2012-11-30	2013-11-27	Anti-vegf antibodies and their uses

Publications (2)

Publication Number	Publication Date
JP2016505546A JP2016505546A (ja)	2016-02-25
JP2016505546A5 true JP2016505546A5 (2)	2017-01-12

Family

ID=49765713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2015545453A Ceased JP2016505546A (ja)	2012-11-30	2013-11-27	抗ｖｅｇｆ抗体及びこれらの使用

Country Status (11)

Country	Link
US (2)	US20140154255A1 (2)
EP (1)	EP2925778B1 (2)
JP (1)	JP2016505546A (2)
CN (1)	CN104903348A (2)
AU (1)	AU2013352127A1 (2)
BR (1)	BR112015012538A2 (2)
CA (1)	CA2892164A1 (2)
ES (1)	ES2649966T3 (2)
HK (1)	HK1215446A1 (2)
MX (1)	MX2015006859A (2)
WO (1)	WO2014085654A1 (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3485903T (lt)	2011-09-23	2023-02-27	Mereo Biopharma 5, Inc.	Vegf/ dll4 surišantys agentai ir jų panaudojimas
US20140154255A1 (en) *	2012-11-30	2014-06-05	Abbvie Biotherapeutics Inc.	Anti-vegf antibodies and their uses
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
CA2957717C (en)	2014-08-12	2021-10-19	Massachusetts Institute Of Technology	Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US11339213B2 (en)	2015-09-23	2022-05-24	Mereo Biopharma 5, Inc.	Methods and compositions for treatment of cancer
PE20181363A1 (es) *	2015-09-23	2018-08-27	Genentech Inc	Variantes optimizadas de anticuerpos anti-vegf
KR20250057128A (ko)	2015-12-30	2025-04-28	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
KR102293753B1 (ko) *	2016-01-06	2021-08-24	오더-메이드 메디컬 리서치 인코포레이티드	Vegf 와 nrp1 의 결합을 저해하는 항체
SG11201808426XA (en) *	2016-04-15	2018-10-30	Univ Pennsylvania	Compositions for treatment of wet age-related macular degeneration
CA3077518C (en) *	2016-09-07	2021-10-19	Frederic Fellouse	Synthetic antibodies against vegf and their uses
IL268959B2 (en)	2017-02-28	2025-01-01	Seagen Inc	Cystine-mutated antibodies, compositions containing them and uses thereof
WO2018213064A1 (en)	2017-05-19	2018-11-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
CN110003328B (zh) *	2018-01-05	2022-04-19	百奥泰生物制药股份有限公司	一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
EP3758737A4 (en)	2018-03-02	2022-10-12	Kodiak Sciences Inc.	IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CN109053895B (zh)	2018-08-30	2020-06-09	中山康方生物医药有限公司	抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CA3157509A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
CN111363038A (zh) *	2020-03-26	2020-07-03	北京纽安博生物技术有限公司	抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用
US20240317873A1 (en) *	2021-03-16	2024-09-26	City Of Hope	Anti-hvem antibodies
US20250367255A1 (en)	2021-11-08	2025-12-04	Pfizer Inc.	Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
WO1996033735A1 (en)	1995-04-27	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
US5264586A (en)	1991-07-17	1993-11-23	The Scripps Research Institute	Analogs of calicheamicin gamma1I, method of making and using the same
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1996034096A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
CA2722378C (en)	1996-12-03	2015-02-03	Amgen Fremont Inc.	Human antibodies that bind tnf.alpha.
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
US20070059302A1 (en)	1997-04-07	2007-03-15	Genentech, Inc.	Anti-vegf antibodies
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
PT971959E (pt)	1997-04-07	2006-05-31	Genentech Inc	Anticorpos humanizados e metodos para formar anticorpos humanizados
BRPI9809391B8 (pt)	1997-04-14	2021-05-25	Amgen Res Munich Gmbh	processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
AU1728800A (en)	1998-11-18	2000-06-05	Genentech Inc.	Antibody variants with higher binding affinity compared to parent antibodies
EP1950300A3 (en)	1998-11-18	2011-03-23	Genentech, Inc.	Antibody variants with higher binding affinity compared to parent antibodies
DK1140173T4 (da)	1998-12-22	2013-06-10	Genentech Inc	Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
US6979559B2 (en)	2000-10-12	2005-12-27	Marical, Inc.	Polyvalent cation-sensing receptor in atlantic salmon
US6979556B2 (en)	2000-12-14	2005-12-27	Genentech, Inc.	Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
JP4056880B2 (ja)	2000-12-14	2008-03-05	ジェネンテック・インコーポレーテッド	細菌性宿主株
WO2002061090A2 (en)	2000-12-14	2002-08-08	Genentech, Inc.	Prokaryotically produced antibodies and uses thereof
CA2369893A1 (en)	2001-02-12	2002-08-12	Warner-Lambert Company	Vegf responsive cell-based assay for determining vegf bioactivity
US20030022240A1 (en)	2001-04-17	2003-01-30	Peizhi Luo	Generation and affinity maturation of antibody library in silico
US7117096B2 (en)	2001-04-17	2006-10-03	Abmaxis, Inc.	Structure-based selection and affinity maturation of antibody library
US20040010376A1 (en)	2001-04-17	2004-01-15	Peizhi Luo	Generation and selection of protein library in silico
US7667004B2 (en)	2001-04-17	2010-02-23	Abmaxis, Inc.	Humanized antibodies against vascular endothelial growth factor
US6884869B2 (en)	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
WO2003068801A2 (en)	2002-02-11	2003-08-21	Genentech, Inc.	Antibody variants with faster antigen association rates
WO2003099999A2 (en)	2002-05-20	2003-12-04	Abmaxis, Inc.	Generation and selection of protein library in silico
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004042017A2 (en)	2002-10-31	2004-05-21	Genentech, Inc.	Methods and compositions for increasing antibody production
EP1585768A2 (en)	2003-01-23	2005-10-19	Genentech, Inc.	Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
UA101945C2 (uk)	2003-05-30	2013-05-27	Дженентек, Инк.	Лікування злоякісного новоутворення за допомогою бевацизумабу
DK3095793T3 (da)	2003-07-28	2020-05-25	Genentech Inc	Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
AU2004261980A1 (en) *	2003-08-01	2005-02-10	Genentech, Inc.	Antibody CDR polypeptide sequences with restricted diversity
US20050106667A1 (en) *	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) *	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
EP2478912B1 (en)	2003-11-06	2016-08-31	Seattle Genetics, Inc.	Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005123780A2 (en)	2004-04-09	2005-12-29	Protein Design Labs, Inc.	Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US20070059336A1 (en)	2004-04-30	2007-03-15	Allergan, Inc.	Anti-angiogenic sustained release intraocular implants and related methods
US20060182783A1 (en)	2004-04-30	2006-08-17	Allergan, Inc.	Sustained release intraocular drug delivery systems
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
AU2005285347A1 (en)	2004-08-19	2006-03-23	Genentech, Inc.	Polypeptide variants with altered effector function
RU2007117716A (ru)	2004-10-12	2008-11-20	Ампротеин Корпорейшн (Us)	Химерный белок
EP1799246A4 (en)	2004-10-12	2009-08-12	Amprotein Corp	CHIMERIC PROTEIN
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
AU2005335714B2 (en)	2004-11-10	2012-07-26	Macrogenics, Inc.	Engineering Fc antibody regions to confer effector function
US20080207467A1 (en)	2005-03-03	2008-08-28	Xencor, Inc.	Methods for the design of libraries of protein variants
US8716195B2 (en)	2005-11-14	2014-05-06	Bioren, Inc.	Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
WO2007059336A1 (en)	2005-11-18	2007-05-24	Nextrom Oy	Method and apparatus for manufacturing water-free optical fiber preforms
EP1957541A2 (en)	2005-11-21	2008-08-20	Laboratoires Serono SA	Compositions and methods of producing hybrid antigen binding molecules and uses thereof
MX2008009494A (es)	2006-01-23	2009-01-07	Joseph P Errico	Metodos y composiciones de desarrollo dirigido de farmacos.
ES2820837T3 (es)	2006-07-10	2021-04-22	Esbatech Alcon Biomed Res Unit	Anticuerpos scFv que pasan las capas epitelial y/o endotelial
US11078262B2 (en)	2007-04-30	2021-08-03	Allergan, Inc.	High viscosity macromolecular compositions for treating ocular conditions
KR102055873B1 (ko)	2007-07-09	2019-12-13	제넨테크, 인크.	폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
WO2009129538A2 (en) *	2008-04-18	2009-10-22	Xencor, Inc.	Human equivalent monoclonal antibodies engineered from nonhuman variable regions
SG190572A1 (en) *	2008-04-29	2013-06-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
EP2443150B1 (en) *	2009-06-17	2015-01-21	AbbVie Biotherapeutics Inc.	Anti-vegf antibodies and their uses
UY32808A (es)	2009-07-29	2011-02-28	Abbott Lab	Inmunoglobulinas como dominio variable dual y usos de las mismas
WO2011028952A1 (en) *	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR101853278B1 (ko)	2010-03-02	2018-05-02	애브비 인코포레이티드	치료학적 ｄｌｌ４ 결합 단백질
US20120077691A1 (en)	2010-09-24	2012-03-29	Full Spectrum Genetics, Inc.	Method of analyzing binding interactions
MX2013004979A (es) *	2010-11-02	2013-07-30	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
US20140161790A1 (en) *	2012-11-19	2014-06-12	Xencor, Inc.	Engineered immunoglobulins with extended in vivo half-life
US20140154255A1 (en) *	2012-11-30	2014-06-05	Abbvie Biotherapeutics Inc.	Anti-vegf antibodies and their uses

2013
- 2013-11-26 US US14/090,361 patent/US20140154255A1/en not_active Abandoned
- 2013-11-27 AU AU2013352127A patent/AU2013352127A1/en not_active Abandoned
- 2013-11-27 ES ES13805701.3T patent/ES2649966T3/es active Active
- 2013-11-27 JP JP2015545453A patent/JP2016505546A/ja not_active Ceased
- 2013-11-27 EP EP13805701.3A patent/EP2925778B1/en not_active Not-in-force
- 2013-11-27 US US14/648,385 patent/US9815893B2/en not_active Expired - Fee Related
- 2013-11-27 CA CA2892164A patent/CA2892164A1/en not_active Abandoned
- 2013-11-27 MX MX2015006859A patent/MX2015006859A/es unknown
- 2013-11-27 BR BR112015012538A patent/BR112015012538A2/pt not_active IP Right Cessation
- 2013-11-27 WO PCT/US2013/072335 patent/WO2014085654A1/en not_active Ceased
- 2013-11-27 CN CN201380069058.5A patent/CN104903348A/zh active Pending
- 2013-11-27 HK HK16103416.2A patent/HK1215446A1/zh unknown

Publication	Publication Date	Title
JP2016505546A5 (2)	2017-01-12
RU2019141289A (ru)	2021-06-16	АНТИ-SIRPα АНТИТЕЛА
JP2018183173A5 (2)	2019-01-24
JP2018505177A5 (2)	2019-03-22
JP2016512551A5 (2)	2017-04-06
JP2012530496A5 (2)	2013-08-01
JP2011046732A5 (2)	2012-01-05
JP2021514973A5 (2)	2022-03-07
JP2017534577A5 (2)	2018-10-25
JP2019501883A5 (2)	2020-01-23
JP2016536020A5 (2)	2017-08-10
JP2023134618A5 (2)	2024-04-03
JP2024056687A5 (2)	2024-09-06
JP2019536806A5 (2)	2021-01-21
JP2020520370A5 (2)	2021-07-26
JP2015509947A5 (2)	2016-04-07
JP2018510617A5 (2)	2019-03-07
JP2018506277A5 (2)	2019-03-07
JP2018035138A5 (2)	2019-02-14
JP2011506483A5 (2)	2012-02-09
JP2014158469A5 (2)	2014-10-16
JP2017535257A5 (2)	2018-11-08
HRP20201928T1 (hr)	2021-02-05	Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
JP2018507220A5 (2)	2019-04-04
RU2017102514A (ru)	2018-07-31	Гуманизированные анти-тау-антитела